Spruce Biosciences, Inc.
SPRB
Rank in Stocks
#18184
Spruce Biosciences, Inc., founded in 2014 and situated in Daly City,... Spruce Biosciences, Inc., founded in 2014 and situated in Daly City, California, operates as a biopharmaceutical enterprise. Its primary objective is to advance and bring to market innovative treatments, particularly for uncommon endocrine conditions. A central component of its therapeutic pipeline is tildacerfont, a non-steroidal drug candidate. This compound is currently undergoing Phase 2b clinical assessments in adult patients with congenital adrenal hyperplasia (CAH), with the aim of optimizing disease management and lessening dependence on steroid medications by examining reductions in glucocorticoid levels and their clinical consequences. Tildacerfont is also progressing through Phase 2 trials for pediatric classic CAH, as well as investigating its efficacy in women suffering from polycystic ovary syndrome (PCOS). Additionally, Spruce Biosciences maintains a collaborative licensing agreement with Eli Lilly and Company to jointly explore, formulate, and commercialize various pharmaceutical substances.
Share Price
$49.34
Last synced: 2026-11-09
Market Cap
$141.80M
Change (1 day)
5.99%
Change (1 year)
-56.20%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Spruce Biosciences, Inc. (SPRB)
Category
Healthcare
EPS for Spruce Biosciences, Inc. (SPRB)
EPS as of June 2026 TTM: $-40.87
According to Spruce Biosciences, Inc.'s latest financial reports, its current EPS (TTM) is $-40.87. At the end of 2025 the company had an EPS of $-50.83, an increase over its 2024 EPS of $-96.75.
EPS history for Spruce Biosciences, Inc. from 2018 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-40.87 | -19.59% |
| 2025 | $-50.83 | -47.46% |
| 2024 | $-96.75 | 4.03% |
| 2023 | $-93.00 | 29.17% |
| 2022 | $-72.00 | 5.49% |
| 2021 | $-68.25 | 40.00% |
| 2020 | $-48.75 | 116.67% |
| 2019 | $-22.50 | -95.35% |
| 2018 | $-483.75 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -138.32% |
US
|
|
| $-7.07 | -82.70% |
US
|
|
| $-5.29 | -87.06% |
AU
|
|
| $12.88 | -131.51% |
BE
|
|
| $21.56 | -152.75% |
NL
|
Questions about Spruce Biosciences, Inc.'s earnings per share (EPS)
What is Spruce Biosciences, Inc.'s earnings per share (EPS)?
Spruce Biosciences, Inc.'s earnings per share (EPS) over the last twelve months is $-40.87, as of Jun 2026.
What was Spruce Biosciences, Inc.'s earnings per share (EPS) in 2025?
In 2025, Spruce Biosciences, Inc.'s earnings per share (EPS) was $-50.83, compared with $-96.75 in 2024.
How has Spruce Biosciences, Inc.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, Spruce Biosciences, Inc.'s earnings per share (EPS) was highest in 2020 ($-48.75) and lowest in 2024 ($-96.75).
How does Spruce Biosciences, Inc.'s earnings per share (EPS) compare with similar companies?
Spruce Biosciences, Inc.'s earnings per share (EPS) ($-40.87) is lower than that of all 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.